Design of Potent Bivalent Thrombin Inhibitors Based on Hirudin Sequence: Incorporation of Nonsubstrate-Type Active Site Inhibitors
- 6 December 1994
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 33 (48) , 14443-14451
- https://doi.org/10.1021/bi00252a010
Abstract
Hirudin from medicinal leech is the most potent and specific thrombin inhibitor from medicinal leech with a Ki value of 2.2 \ud7 10\u207b\ub9\u2074 M. It consists of an active site blocking moiety, hirudin\ub9\u207b\u2074\u2078, a fibrinogen-recognition exo-site binding moiety, hirudin\u2075\u2075\u207b\u2076\u2075, and a lilnker, hirudin\u2074\u2079\u207b\u2075\u2074, connecting these inhibitor moieties. Synthetic inhibitors were designed based on the C-terminal portion of hirudin. The bulky active site blocking moiety, hirudin\ub9\u207b\u2074\u2078, was replaced by small nonsubstrate-type active site ibhibitors of thrombin, e.q., dansyl-Arg-(D-pipecolic acid). The linker moiety was replaced by \u3c9-amino acids of (12-aminododecanoic acid)-(4-aminobutyric acid), and hirudin\u2075\u2075\u207b\u2076\u2075 was used as a fibrinogen-recognition exo-site binding moiety in most of the inhibitors. The crystal structure of the inhibitor in complex with human \u3b1-thrombin showed that dansyl, Arg, and D-pipecolic acid of the active site blocking moiety occupy S3, S1, and S2 subsites of thrombin, respectively, and were therefore designated as P3, P1, and P2 residues. The use of dansyl-Arg-(D-pipecolic acid) improved the affinity (Ki) of the inihibitor 10-100-fold (down to 1.70 \ud7 10\u207b\ub9\ub9 M) comparted to that of the similar compounds having D-Phe-Pro-Arg as their substrate-type inhibitor moiety (Ki = 10\u207b\u2079-10\u207b\ub9\uba M). The linker connected to P2 residue eliminated teh scissle peptide bond. The inhibitor was also stable against human plasma proteases. Further inhibitor design revealed that the toxic dansyl group could be replaced by 4-tert-butylbenzenesulfonyl group and 1- or 2-naphthalenesulfonyl group for in vivo studies. In addition, the replacement of hirudin\u2075\u2075\u207b\u2076\u2075 with [Tyr\u2075\u2076,-Pro\u2075\u2078,Ala\u2076\ub3,Cha\u2076\u2074,D-Glu\u2076\u2075]hirudin\u2075\u2075\u207b\u2076\u2075 improved the affinity of the inhibitors (Ki = 2.0 \ud7 10\u207b\ub9\ub3 M).Peer reviewed: NoNRC publication: YeKeywords
This publication has 37 references indexed in Scilit:
- Synthesis of a homologous series of ketomethylene arginyl pseudodipeptides and application to low molecular weight hirudin-like thrombin inhibitorsJournal of Medicinal Chemistry, 1992
- Refined 2·3ÅX-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA: A starting point for improving antithromboticsJournal of Molecular Biology, 1992
- New peptide boronic acid inhibitors of thrombinTetrahedron Letters, 1992
- Structure‐function relationships of hirulog peptide interactions with thrombinFEBS Letters, 1991
- Substrate-related phosphonopeptides, a new class of thrombin inhibitorsTetrahedron Letters, 1991
- Effects of Hirudin and Heparin on the Binding of New Fibrin to the Thrombus in t-PA Treated RabbitsThrombosis and Haemostasis, 1991
- Hirudin and other thrombin inhibitors experimental results and potential clinical applicationsTrends in Cardiovascular Medicine, 1991
- A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bondFEBS Letters, 1991
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 1987
- Synthesis and biological actions of highly potent and prolonged acting biotin-labeled melanotropinsJournal of Medicinal Chemistry, 1984